<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703961</url>
  </required_header>
  <id_info>
    <org_study_id>XJFL-2016-02-LACC-TP triweekly</org_study_id>
    <nct_id>NCT02703961</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer</brief_title>
  <official_title>Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment of local advanced cervical cancer is concurrent chemoradiotherapy. The
      3 year disease free survival was about 50-70%. The distant metastasis is the main cause of
      failure in local advanced cervical cancer treated with 3-dimensional conformal radiotherapy
      (3D-CRT) or intensity modulated radiotherapy (IMRT). The purpose of this study is to
      investigate the efficacy and tolerance of concurrent and adjuvant chemotherapy with cisplatin
      and docetaxel for local advanced cervical cancer. It was expected that the 3 year disease
      free survival would be increased by 10% with this new treatment schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cervical cancer is the most common malignant gynecological tumor in the developing area.
      From 1999, the concurrent chemoradiotherapy has been established as the standard treatment
      for local advanced cervical cancer. The modern radiotherapy techniques, such as 3 dimensional
      conformal radiotherapy(3D-CRT), intensity modulated radiotherapy(IMRT), image guided
      3-dimensional brachytherapy(3D-BT), was widely used for the treatment of cervical cancer. The
      recently clinical outcome showed that the 3 year local and regional control was more than
      90%［1-3］. The distant metastasis has proved to be the main cause of failure and death,
      especially for the patient with pelvic lymph node metastasis, large volume of tumor and
      advanced FIGO stage. the data showed that the 3 year distant metastasis free survival and
      overall survival were 64.7% and 64.6% respectively for the patient with huge pelvic lymph
      node metastasis and FIGO stage III- IVA. The system treatment pointing at the distant
      metastasis has become to be the topic of clinical investigation.

      Dueñas-González A`［4］ study demonstrated that the 3 year progress free survival and distant
      metastasis free survival has increased by 8.9% and 8.3% by the radial radiotherapy combined
      with concurrent chemotherapy with weekly gemcitabine and cisplatin and adjuvant chemotherapy
      with triweekly gemcitabine and cisplatin. Ryu SY［5］ also reported the triweekly concurrent
      cisplatin with 3 cycles improved survival outcomes compared with weekly concurrent cisplatin.
      Retrospective studies by Tang and Jelavić-TB［6-7］ suggested that the adjubant chemotherapy
      after CCRT has better DMFS and OS.

      The aim of present study is to prospectively investigate the efficacy and safety of
      concurrent and adjuvant chemotherapy with cisplatin and docetaxel for patients with local
      advanced cervical cancer, especially for those with FIGO III-IVA with or without pelvic lymph
      node metastasis and the FIGO IB2-IIB with pelvic lymph node metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">598</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.
During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.
After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;
The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
docetaxel 75mg/m2, d43,d64.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard chemoradiotherapy with weekly cisplatin.
Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.
Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy with cisplatin</intervention_name>
    <description>in experimental group: cisplatin 60mg/m2, d1,d22;</description>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy with docetaxel</intervention_name>
    <description>in experimental group: docetaxel 60mg/m2, d1,d22;</description>
    <arm_group_label>experimental</arm_group_label>
    <other_name>docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>pelvic radiotherapy</intervention_name>
    <description>external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.</description>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>external beam radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>CT/MRI guided brachytherapy or x-ray guided brachytherapy</description>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant chemotherapy with cisplatin and docetaxel</intervention_name>
    <description>cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or
             adenosquamouscarcinoma of the cervix

          2. FIGO clinical stage IB2-IIB with pelvic lymph node metastasis or FIGO clinical stage
             III-IVA with or without pelvic lymph node metastasis

          3. ECOG performance score 0-1

          4. The bone marrow, hepatic and renal function was normal at registration

          5. The patients signed informed consent

        Exclusion Criteria:

          1. clear cell and small cell neuroendocrine, sarcoma

          2. FIGO stage IVB

          3. Prior invasive malignancy

          4. Prior systemic chemotherapy

          5. Prior radiotherapy to the pelvis or abdomen

          6. Severe, active co-morbidity

          7. Women who are pregnant

          8. immunocompromised status
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mei shi, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital, the Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mei shi, professor</last_name>
    <phone>0086-029-84775432</phone>
    <email>mshi82@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ying zhang, doctor</last_name>
    <phone>0086-029-84775432</phone>
    <email>yingzhang@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing hospital, the Fourth Military Medical University</name>
      <address>
        <city>Xi` An</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Shi, professor</last_name>
      <phone>0086-029-84775432</phone>
      <email>mshi82@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>ying zhang, doctor</last_name>
      <phone>0086-029-84775432</phone>
      <email>zhangying@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Shi, MM</last_name>
      <phone>+86-029-84775425</phone>
      <email>mshi82@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Mei Shi, MM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Xijing Hospital, Fourth Military</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Shi, MD</last_name>
      <phone>86-29-84775425</phone>
      <email>Shimei82@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jelavić TB, Miše BP, Strikic A, Ban M, Vrdoljak E. Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy--Room for Improvement? Anticancer Res. 2015 Jul;35(7):4161-5.</citation>
    <PMID>26124372</PMID>
  </reference>
  <results_reference>
    <citation>Tharavichitkul E, Chakrabandhu S, Wanwilairat S, Tippanya D, Nobnop W, Pukanhaphan N, Galalae RM, Chitapanarux I. Intermediate-term results of image-guided brachytherapy and high-technology external beam radiotherapy in cervical cancer: Chiang Mai University experience. Gynecol Oncol. 2013 Jul;130(1):81-5. doi: 10.1016/j.ygyno.2013.04.018. Epub 2013 Apr 17.</citation>
    <PMID>23603369</PMID>
  </results_reference>
  <results_reference>
    <citation>Gill BS, Kim H, Houser CJ, Kelley JL, Sukumvanich P, Edwards RP, Comerci JT, Olawaiye AB, Huang M, Courtney-Brooks M, Beriwal S. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):540-7. doi: 10.1016/j.ijrobp.2014.10.053. Epub 2015 Jan 30.</citation>
    <PMID>25680598</PMID>
  </results_reference>
  <results_reference>
    <citation>Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JAM, Sethi RA, Chan JK, Hsu IC. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1093-1100. doi: 10.1016/j.ijrobp.2015.04.018. Epub 2015 Jul 14.</citation>
    <PMID>26194683</PMID>
  </results_reference>
  <results_reference>
    <citation>Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28.</citation>
    <PMID>21444871</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81. doi: 10.1016/j.ijrobp.2011.05.002. Epub 2011 Aug 11.</citation>
    <PMID>21840137</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang J, Tang Y, Yang J, Huang S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol. 2012 May;125(2):297-302. doi: 10.1016/j.ygyno.2012.01.033. Epub 2012 Jan 31.</citation>
    <PMID>22307061</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Mei Shi</investigator_full_name>
    <investigator_title>chair of department</investigator_title>
  </responsible_party>
  <keyword>CCRT</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>cisplatin and docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

